BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 20097068)

  • 1. Pyrrolidine amides of pyrazolodihydropyrimidines as potent and selective KV1.5 blockers.
    Lloyd J; Finlay HJ; Vacarro W; Hyunh T; Kover A; Bhandaru R; Yan L; Atwal K; Conder ML; Jenkins-West T; Shi H; Huang C; Li D; Sun H; Levesque P
    Bioorg Med Chem Lett; 2010 Feb; 20(4):1436-9. PubMed ID: 20097068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacophore-based search, synthesis, and biological evaluation of anthranilic amides as novel blockers of the Kv1.5 channel.
    Peukert S; Brendel J; Pirard B; Strübing C; Kleemann HW; Böhme T; Hemmerle H
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2823-7. PubMed ID: 15125940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aryl sulfonamido indane inhibitors of the Kv1.5 ion channel.
    Gross MF; Beaudoin S; McNaughton-Smith G; Amato GS; Castle NA; Huang C; Zou A; Yu W
    Bioorg Med Chem Lett; 2007 May; 17(10):2849-53. PubMed ID: 17350840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent antagonists of the Kv1.5 potassium channel: synthesis and evaluation of analogous N,N-diisopropyl-2-(pyridine-3-yl)acetamides.
    Nanda KK; Nolt MB; Cato MJ; Kane SA; Kiss L; Spencer RH; Wang J; Lynch JJ; Regan CP; Stump GL; Li B; White R; Yeh S; Bogusky MJ; Bilodeau MT; Dinsmore CJ; Lindsley CW; Hartman GD; Wolkenberg SE; Trotter BW
    Bioorg Med Chem Lett; 2006 Nov; 16(22):5897-901. PubMed ID: 16949818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of thiazolidine-based blockers of human Kv1.5 for the treatment of atrial arrhythmias.
    Jackson CM; Blass B; Coburn K; Djandjighian L; Fadayel G; Fluxe AJ; Hodson SJ; Janusz JM; Murawsky M; Ridgeway JM; White RE; Wu S
    Bioorg Med Chem Lett; 2007 Jan; 17(1):282-4. PubMed ID: 17095219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and evaluation of (2-phenethyl-2H-1,2,3-triazol-4-yl)(phenyl)methanones as Kv1.5 channel blockers for the treatment of atrial fibrillation.
    Blass BE; Coburn K; Lee W; Fairweather N; Fluxe A; Wu S; Janusz JM; Murawsky M; Fadayel GM; Fang B; Hare M; Ridgeway J; White R; Jackson C; Djandjighian L; Hedges R; Wireko FC; Ritter AL
    Bioorg Med Chem Lett; 2006 Sep; 16(17):4629-32. PubMed ID: 16793267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and evaluation of phenethylaminoheterocycles as K(v)1.5 inhibitors.
    Johnson JA; Xu N; Jeon Y; Finlay HJ; Kover A; Conder ML; Sun H; Li D; Levesque P; Hsueh MM; Harper TW; Wexler RR; Lloyd J
    Bioorg Med Chem Lett; 2014 Jul; 24(14):3018-22. PubMed ID: 24881565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dihydropyrazolopyrimidines containing benzimidazoles as K(V)1.5 potassium channel antagonists.
    Lloyd J; Finlay HJ; Atwal K; Kover A; Prol J; Yan L; Bhandaru R; Vaccaro W; Huynh T; Huang CS; Conder M; Jenkins-West T; Sun H; Li D; Levesque P
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5469-73. PubMed ID: 19665893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and evaluation of diphenylphosphinic amides and diphenylphosphine oxides as inhibitors of Kv1.5.
    Olsson RI; Jacobson I; Boström J; Fex T; Björe A; Olsson C; Sundell J; Gran U; Öhrn A; Nordin A; Gyll J; Thorstensson M; Hayen A; Aplander K; Hidestål O; Jiang F; Linhardt G; Forsström E; Collins T; Sundqvist M; Lindhardt E; Åstrand A; Löfberg B
    Bioorg Med Chem Lett; 2013 Feb; 23(3):706-10. PubMed ID: 23260347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lactam sulfonamides as potent inhibitors of the Kv1.5 potassium ion channel.
    Olsson RI; Jacobson I; Iliefski T; Boström J; Davidsson Ö; Fjellström O; Björe A; Olsson C; Sundell J; Gran U; Gyll J; Malmberg J; Hidestål O; Emtenäs H; Svensson T; Yuan ZQ; Strandlund G; Åstrand A; Lindhardt E; Linhardt G; Forsström E; Högberg Å; Persson F; Andersson B; Rönnborg A; Löfberg B
    Bioorg Med Chem Lett; 2014 Mar; 24(5):1269-73. PubMed ID: 24513046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudosaccharin amines as potent and selective KV1.5 blockers.
    Lloyd J; Finlay HJ; Kover A; Johnson J; Pi Z; Jiang J; Neels J; Cavallaro C; Wexler R; Conder ML; Shi H; Li D; Sun H; Chimalakonda A; Huang C; Salvati M; Levesque P
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4983-4986. PubMed ID: 25801931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aryl sulfonamido tetralin inhibitors of the Kv1.5 ion channel.
    Gross MF; Castle NA; Zou A; Wickenden AD; Yu W; Spear KL
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3063-6. PubMed ID: 19398199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel, potent inhibitors of human Kv1.5 K+ channels and ultrarapidly activating delayed rectifier potassium current.
    Lagrutta A; Wang J; Fermini B; Salata JJ
    J Pharmacol Exp Ther; 2006 Jun; 317(3):1054-63. PubMed ID: 16522807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification, synthesis, and activity of novel blockers of the voltage-gated potassium channel Kv1.5.
    Peukert S; Brendel J; Pirard B; Brüggemann A; Below P; Kleemann HW; Hemmerle H; Schmidt W
    J Med Chem; 2003 Feb; 46(4):486-98. PubMed ID: 12570371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological evaluation of arylmethylpiperidines as Kv1.5 potassium channel inhibitors.
    Zhao L; Yang Q; Tang Y; You Q; Guo X
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):462-471. PubMed ID: 35012386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and characterization of pyrrolidine diastereoisomers as potent functional agonists and antagonists of the human melanocortin-4 receptor.
    Chen C; Jiang W; Tran JA; Tucci FC; Fleck BA; Markison S; Wen J; Madan A; Hoare SR; Foster AC; Marinkovic D; Chen CW; Arellano M; Saunders J
    Bioorg Med Chem Lett; 2008 Jan; 18(1):129-36. PubMed ID: 18032040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triazolo and imidazo dihydropyrazolopyrimidine potassium channel antagonists.
    Finlay HJ; Jiang J; Caringal Y; Kover A; Conder ML; Xing D; Levesque P; Harper T; Hsueh MM; Atwal K; Blanar M; Wexler R; Lloyd J
    Bioorg Med Chem Lett; 2013 Mar; 23(6):1743-7. PubMed ID: 23414837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel.
    Beshore DC; Liverton NJ; McIntyre CJ; Claiborne CF; Libby B; Culberson JC; Salata JJ; Regan CP; Lynch JJ; Kiss L; Spencer RH; Kane SA; White RB; Yeh S; Hartman GD; Dinsmore CJ
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2493-6. PubMed ID: 20304642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benzopyran sulfonamides as KV1.5 potassium channel blockers.
    Lloyd J; Atwal KS; Finlay HJ; Nyman M; Huynh T; Bhandaru R; Kover A; Schmidt J; Vaccaro W; Conder ML; Jenkins-West T; Levesque P
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3271-5. PubMed ID: 17462888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Khellinone derivatives as blockers of the voltage-gated potassium channel Kv1.3: synthesis and immunosuppressive activity.
    Baell JB; Gable RW; Harvey AJ; Toovey N; Herzog T; Hänsel W; Wulff H
    J Med Chem; 2004 Apr; 47(9):2326-36. PubMed ID: 15084131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.